HK1257190A1 - 抗假單胞菌psl結合分子及其用途 - Google Patents
抗假單胞菌psl結合分子及其用途Info
- Publication number
- HK1257190A1 HK1257190A1 HK18116167.3A HK18116167A HK1257190A1 HK 1257190 A1 HK1257190 A1 HK 1257190A1 HK 18116167 A HK18116167 A HK 18116167A HK 1257190 A1 HK1257190 A1 HK 1257190A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding molecules
- pseudomonas psl
- psl binding
- pseudomonas
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161495460P | 2011-06-10 | 2011-06-10 | |
US201161530461P | 2011-09-02 | 2011-09-02 | |
US201261613317P | 2012-03-20 | 2012-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257190A1 true HK1257190A1 (zh) | 2019-10-18 |
Family
ID=47296761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116167.3A HK1257190A1 (zh) | 2011-06-10 | 2018-12-18 | 抗假單胞菌psl結合分子及其用途 |
Country Status (22)
Country | Link |
---|---|
US (4) | US9403901B2 (zh) |
EP (2) | EP2718320B1 (zh) |
JP (2) | JP6058645B2 (zh) |
KR (1) | KR102111171B1 (zh) |
CN (1) | CN103974975B (zh) |
AU (3) | AU2012267732A1 (zh) |
BR (1) | BR112013031485B1 (zh) |
CA (1) | CA2838211C (zh) |
CY (1) | CY1120557T1 (zh) |
DK (1) | DK2718320T3 (zh) |
ES (1) | ES2664972T3 (zh) |
HK (1) | HK1257190A1 (zh) |
HR (1) | HRP20180458T1 (zh) |
HU (1) | HUE038509T2 (zh) |
LT (1) | LT2718320T (zh) |
MX (1) | MX349886B (zh) |
PL (1) | PL2718320T3 (zh) |
PT (1) | PT2718320T (zh) |
RS (1) | RS57024B1 (zh) |
RU (2) | RU2014100111A (zh) |
SI (1) | SI2718320T1 (zh) |
WO (1) | WO2012170807A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE038509T2 (hu) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Pseudomonas PSL elleni kötõmolekula és alkalmazása |
CA3161431A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune Limited | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
CN104995209A (zh) * | 2012-11-06 | 2015-10-21 | 米迪缪尼有限公司 | 使用抗假单胞菌Psl和PcrV结合分子的联合治疗 |
AU2014265632B2 (en) * | 2013-05-14 | 2019-09-19 | Medimmune, Llc | Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
SG10201913100WA (en) | 2015-11-30 | 2020-03-30 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
PL3365368T3 (pl) | 2016-03-11 | 2023-08-21 | Scholar Rock, Inc. | Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie |
CN110072554A (zh) * | 2016-05-05 | 2019-07-30 | 宾夕法尼亚大学理事会 | 用于抗铜绿假单胞菌的dna抗体构建体 |
WO2018186225A1 (ja) | 2017-04-03 | 2018-10-11 | 富士フイルム株式会社 | インク組成物及びその製造方法、並びに画像形成方法 |
GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
US20220153819A1 (en) | 2019-02-12 | 2022-05-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
JP7474393B2 (ja) | 2020-04-22 | 2024-04-25 | センクシア株式会社 | アンカーボルトの施工方法、及びその方法に使用する箱抜き用型枠 |
EP4192856A1 (en) * | 2020-08-07 | 2023-06-14 | Beijing SoloBio Genetechnology Company Ltd. | Antibodies specifically recognizing pseudomonas psl and uses thereof |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
ATE77243T1 (de) * | 1985-03-11 | 1992-07-15 | Teijin Ltd | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
AU8619698A (en) | 1997-07-25 | 1999-02-16 | Ban C. H. Tsui | Devices, systems and methods for determining proper placement of epidural catheters |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) * | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
US7553936B2 (en) | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
EA201000903A1 (ru) * | 2007-11-30 | 2011-02-28 | Калобиос Фармасьютикалс, Инк. | Антитела к pcrv-антигену pseudomonas aeruginosa |
KR101259239B1 (ko) | 2008-01-10 | 2013-04-29 | 시오노기세야쿠 가부시키가이샤 | PcrV에 대한 항체 |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
WO2010062896A1 (en) | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CA2751433A1 (en) | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
WO2010107778A1 (en) | 2009-03-18 | 2010-09-23 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
WO2010108153A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
WO2010115606A1 (en) * | 2009-04-09 | 2010-10-14 | Kenta Biotech Ag | Human monoclonal antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa |
WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
WO2011087799A1 (en) | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
DK2673373T6 (da) | 2011-02-08 | 2021-08-23 | Medimmune Llc | Antistoffer, der binder specifikt til staphylococcus aureus alfa-toksin, og fremgangsmåder til anvendelse |
HUE038509T2 (hu) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Pseudomonas PSL elleni kötõmolekula és alkalmazása |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
CA3161431A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune Limited | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
RU2661406C2 (ru) | 2012-11-06 | 2018-07-16 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения заболеваний, ассоциированных с s. aureus |
CN104995209A (zh) | 2012-11-06 | 2015-10-21 | 米迪缪尼有限公司 | 使用抗假单胞菌Psl和PcrV结合分子的联合治疗 |
BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
AU2014265632B2 (en) | 2013-05-14 | 2019-09-19 | Medimmune, Llc | Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof |
WO2015171504A1 (en) | 2014-05-05 | 2015-11-12 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
SG10201913100WA (en) | 2015-11-30 | 2020-03-30 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
CN110072554A (zh) | 2016-05-05 | 2019-07-30 | 宾夕法尼亚大学理事会 | 用于抗铜绿假单胞菌的dna抗体构建体 |
JP6988094B2 (ja) | 2017-01-27 | 2022-01-05 | 富士フイルムビジネスイノベーション株式会社 | ポリイミド前駆体組成物、及びポリイミド成形体の製造方法 |
-
2012
- 2012-06-08 HU HUE12796646A patent/HUE038509T2/hu unknown
- 2012-06-08 BR BR112013031485-0A patent/BR112013031485B1/pt active IP Right Grant
- 2012-06-08 US US14/125,073 patent/US9403901B2/en active Active
- 2012-06-08 PT PT127966463T patent/PT2718320T/pt unknown
- 2012-06-08 JP JP2014514881A patent/JP6058645B2/ja active Active
- 2012-06-08 WO PCT/US2012/041538 patent/WO2012170807A2/en active Application Filing
- 2012-06-08 SI SI201231259T patent/SI2718320T1/en unknown
- 2012-06-08 MX MX2013014372A patent/MX349886B/es active IP Right Grant
- 2012-06-08 ES ES12796646T patent/ES2664972T3/es active Active
- 2012-06-08 EP EP12796646.3A patent/EP2718320B1/en active Active
- 2012-06-08 RS RS20180333A patent/RS57024B1/sr unknown
- 2012-06-08 KR KR1020137035124A patent/KR102111171B1/ko active IP Right Grant
- 2012-06-08 CN CN201280028257.7A patent/CN103974975B/zh active Active
- 2012-06-08 LT LTEP12796646.3T patent/LT2718320T/lt unknown
- 2012-06-08 DK DK12796646.3T patent/DK2718320T3/en active
- 2012-06-08 RU RU2014100111/10A patent/RU2014100111A/ru not_active Application Discontinuation
- 2012-06-08 CA CA2838211A patent/CA2838211C/en active Active
- 2012-06-08 PL PL12796646T patent/PL2718320T3/pl unknown
- 2012-06-08 EP EP17205254.0A patent/EP3385280A1/en active Pending
- 2012-06-08 RU RU2018102606A patent/RU2708977C2/ru active
- 2012-06-08 AU AU2012267732A patent/AU2012267732A1/en not_active Abandoned
-
2016
- 2016-06-24 US US15/192,072 patent/US10370436B2/en active Active
- 2016-12-07 JP JP2016237276A patent/JP6420813B2/ja active Active
-
2017
- 2017-06-29 AU AU2017204447A patent/AU2017204447B2/en active Active
-
2018
- 2018-03-19 HR HRP20180458TT patent/HRP20180458T1/hr unknown
- 2018-03-20 CY CY20181100322T patent/CY1120557T1/el unknown
- 2018-12-18 HK HK18116167.3A patent/HK1257190A1/zh unknown
-
2019
- 2019-05-01 US US16/400,818 patent/US10844114B2/en active Active
- 2019-10-28 AU AU2019257355A patent/AU2019257355A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/073,879 patent/US20210130442A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257190A1 (zh) | 抗假單胞菌psl結合分子及其用途 | |
HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
IL288203B (en) | Meditops and Meditop binding antibodies and their use | |
IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
HK1201453A1 (zh) | 使用抗假單胞菌 結合分子的組合療法 | |
EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
LT2361936T (lt) | Antigeną rišanti molekulė ir jos panaudojimas |